Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen Inc (PGEN) is a clinical-stage biopharmaceutical leader advancing next-generation gene and cell therapies through its proprietary synthetic biology platforms. This page aggregates official news, press releases, and regulatory developments related to PGEN's innovative research in immuno-oncology, autoimmune disorders, and infectious diseases.
Investors and industry professionals will find timely updates on clinical trial progress, strategic partnerships, and technological breakthroughs leveraging PGEN's UltraCAR-T and AdenoVerse platforms. The curated content supports informed decision-making by providing transparent access to the company's scientific advancements and operational milestones.
Key updates include announcements about therapeutic candidate developments, manufacturing innovations, and collaboration agreements that demonstrate PGEN's position at the forefront of precision medicine. All content is sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to Precigen's latest developments in gene-editing technologies and cellular therapeutics. Regularly updated to reflect PGEN's evolving pipeline and strategic initiatives.
Precigen ActoBio announced positive topline results from its ongoing Phase 1b/2a clinical study of AG019 ActoBiotics for treating recent-onset type 1 diabetes (T1D). The treatment targets autoimmune responses by delivering human proinsulin and interleukin-10 to induce regulatory T cells. Results show that 56% of adult patients receiving AG019 monotherapy stabilized or increased C-peptide levels. In combination therapy with teplizumab, 70% of adults and 100% of adolescents had similar results. The therapy appears safe, with no serious adverse events reported, paving the way for future studies.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 11:00 AM ET. The event will be accessible through Precigen's website in the Events & Presentations section. The company focuses on innovative gene and cell therapies targeting urgent diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen aims to advance affordable biotherapeutics and has a robust pipeline moving toward clinical proof-of-concept.
Precigen, Inc. (Nasdaq: PGEN) reported its Q1 2021 financial results, highlighting significant advancements in its clinical trials. The UltraCAR-T therapies, PRGN-3005 and PRGN-3006, showcased promising safety profiles and clinical activities, with ongoing dose escalation phases. The company initiated the PRGN-2012 study, received orphan drug designations for multiple therapies, and anticipates upcoming data presentations. Financially, total revenues fell by 18% to $24.5 million, attributed mainly to decreased collaboration revenues. However, total cash on hand stands at $209.3 million.
Precigen, a biopharmaceutical company, announced that Chief Financial Officer Rick Sterling will step down effective April 2, 2021, by mutual agreement. The company is actively seeking a qualified successor to support its transition from a clinical-stage to a commercial organization. CEO Helen Sabzevari highlighted the importance of this role in maintaining growth momentum and preparing for commercial readiness of their lead products. Precigen specializes in gene and cell therapies aimed at addressing urgent diseases, particularly in immuno-oncology and autoimmune disorders.
On March 23, 2021, Precigen announced that the first patient has been dosed in a Phase I study of PRGN-2012, an off-the-shelf immunotherapy targeting recurrent respiratory papillomatosis (RRP). Recently granted Orphan Drug Designation by the FDA, PRGN-2012 utilizes gorilla adenovector technology to generate immune responses against HPV 6 and HPV 11. The trial aims to assess the safety and tolerability of PRGN-2012, involving up to 12 patients at maximum tolerated doses. This milestone could provide RRP patients with new therapeutic options, reducing the need for repeat surgeries.
Precigen, a biopharmaceutical company, announced that the FDA granted orphan drug designation for its investigational immunotherapy PRGN-2012, aimed at treating recurrent respiratory papillomatosis (RRP). This designation provides access to various incentives that may expedite development and commercialization. PRGN-2012, developed in collaboration with the National Cancer Institute, utilizes gorilla adenovector technology to prompt immune responses against HPV 6 and 11. The condition affects a small population, making novel treatments critically needed. CEO Helen Sabzevari emphasized the urgency for new therapies.
Precigen, Inc. (Nasdaq: PGEN) announced its financial results for Q4 and the full year 2020, reporting total revenues of $103.2 million, up from $90.7 million in 2019. The company experienced a net loss of $103.8 million or $(0.62) per share. Despite challenges, Precigen raised $129.4 million from a public offering in January 2021, ensuring cash support through 2023. Key developments include promising preliminary clinical data for PRGN-3005 and PRGN-3006 UltraCAR-T therapies, paving the way for future trials.
Precigen, Inc. (Nasdaq: PGEN) will release its fourth quarter and full year 2020 financial results after market close on March 1, 2021. A conference call is scheduled for 4:30 PM ET that day to discuss the results and provide a business update. Helen Sabzevari, PhD, President and CEO, will also present at the H.C. Wainwright Virtual Global Life Sciences Conference starting March 9, 2021. The company is focused on advancing gene and cell therapies targeting serious diseases, with ongoing clinical trials and a commitment to innovation in therapeutics.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 12, 2021, at 11:30 AM ET. Investors can access the live webcast through Precigen's website in the Events & Presentations section. Precigen focuses on innovative gene and cell therapies targeting serious diseases, with an emphasis on immuno-oncology, autoimmune disorders, and infectious diseases. For more information, visit www.precigen.com.
Precigen (Nasdaq: PGEN) announced the successful closing of its public offering of common stock, selling 17,250,000 shares at $7.50 each, including an exercised option for 2,250,000 shares. The offering generated approximately $129.4 million in gross proceeds before expenses. Wells Fargo Securities and Stifel served as joint book-running managers, and the offering was made under an effective shelf registration statement. Precigen aims to advance gene and cell therapies in immuno-oncology and other areas.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
